Arrowhead Research | ARWR - Debt


Arrowhead Research reported $366.28M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Agios Pharmaceuticals USD 48.76M 47.62M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
Incyte USD 42.41M 5.29M Jun/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
Ligand Pharmaceuticals USD 5.74M 5.72M Jun/2025
Merck USD 41.37B 5.97B Sep/2025
Moderna USD 741M 4M Jun/2025
Novartis USD 32.64B 1.37B Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
TG Therapeutics USD 245.34M 8.38M Sep/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025
Xencor USD 67.93M 86.45M Jun/2025